Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/46170 |
Resumo: | SOUSA, Bruno Solano de Freitas Souza. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. |
| id |
CRUZ_9787064efb02123ad23f9b4ec542797c |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/46170 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Voysey, MerrynClemens, Sue Ann CostaMadhi, Shabir A.Weckx, Lily YinFolegatti, Pedro MoreiraAley, Parvinder K.Angus, BrianBaillie, Vicky L.Barnabas, Shaun L.Bhorat, Qasim E.Bibi, SagidaBriner, CarmenCicconi, PaolaCollins, Andrea M.Colin-Jones, RachelCutland, Clare L.Darton, Thomas C.Dheda, KeertanDuncan, Christopher J. A.Emary, Katherine R. W.Ewer, Katie J.Fairlie, LeeFeng, ShuoFerreira, Daniela M.Finn, AdamGoodman, Anna L.Green, Catherine M.Green, Christopher A.Heath, Paul T.Hill, CatherineHill, HelenHirsch, IanHodgson, Susanne H. C.Izu, AlaneJackson, SusanJenkin, DanielJoe, Carina C. D.Kerridge, SimonKoen, AnthonetKwatra, GauravLazarus, RajekaLawrie, Alison M.Lelliott, AliceLibri, VincenzoLillie, Patrick J.Mallory, RaburnMendes, Ana V. A.Milan, Eveline PipoloMinassian, Angela M.McGregor, AlastairMorrison, HazelMujadidi, Yama F.Nana, AnushaO’Reilly, Peter J.Padayachee, Sherman D.Pittella, AnaPlested, EmmaPollock, Katrina M.Ramasamy, Maheshi N.Rhead, SarahSchwarzbold, Alexandre V.Singh, NishaSmith, AndrewSong, RinnSnape, Matthew D.Sprinz, EduardoSutherland, Rebecca K.Tarrant, RichardThomson, Emma C.Török, M. EstéeToshner, MarkTurner, David P. J.Vekemans, JohanVillafana, Tonya L.Watson, Marion E. E.Williams, Christopher J.Douglas, Alexander D.Hill, Adrian V. S.Lambe, TeresaGilbert, Sarah C.Pollard, Andrew J.Faust, Saul N.2021-02-25T13:23:52Z2021-02-25T13:23:52Z2021VOYSEY, Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, v. 397, p. 99-111, 2021.0140-6736https://www.arca.fiocruz.br/handle/icict/4617010.1016/S0140-6736(20)32661-1SOUSA, Bruno Solano de Freitas Souza. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Merryn Voysey*, Sue Ann Costa Clemens*, Shabir A Madhi*, Lily Y Weckx*, Pedro M Folegatti*, Parvinder K Aley, Brian Angus, Vicky L Baillie, Shaun L Barnabas, Qasim E Bhorat, Sagida Bibi, Carmen Briner, Paola Cicconi, Andrea M Collins, Rachel Colin-Jones, Clare L Cutland, Thomas C Darton, Keertan Dheda, Christopher J A Duncan, Katherine R W Emary, Katie J Ewer, Lee Fairlie, Saul N Faust, Shuo Feng, Daniela M Ferreira, Adam Finn, Anna L Goodman, Catherine M Green, Christopher A Green, Paul T Heath, Catherine Hill, Helen Hill, Ian Hirsch, Susanne H C Hodgson, Alane Izu, Susan Jackson, Daniel Jenkin, Carina C D Joe, Simon Kerridge, Anthonet Koen, Gaurav Kwatra, Rajeka Lazarus, Alison M Lawrie, Alice Lelliott, Vincenzo Libri, Patrick J Lillie, Raburn Mallory, Ana V A Mendes, Eveline P Milan, Angela M Minassian, Alastair McGregor, Hazel Morrison, Yama F Mujadidi, Anusha Nana, Peter J O’Reilly, Sherman D Padayachee, Ana Pittella, Emma Plested, Katrina M Pollock, Maheshi N Ramasamy, Sarah Rhead, Alexandre V Schwarzbold, Nisha Singh, Andrew Smith, Rinn Song, Matthew D Snape, Eduardo Sprinz, Rebecca K Sutherland, Richard Tarrant, Emma C Thomson, M Estée Török, Mark Toshner, David P J Turner, Johan Vekemans, Tonya L Villafana, Marion E E Watson, Christopher J Williams, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard* on behalf of the Oxford COVID Vaccine Trial Group†. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK (M Voysey DPhil, P K Aley PhD, S Bibi PhD, R Colin-Jones MSc, K R W Emary BM BCh, S Feng PhD, S Kerridge MSc, A Lelliott BMBS, Y F Mujadidi MSc, P J O’Reilly MBChBAO, E Plested, M N Ramasamy DPhil, S Rhead MBChB, N Singh DPhil, R Song MD, M D Snape MD, A J Pollard FMedSci); Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK (P M Folegatti MD, B Angus MD, P Cicconi PhD, K J Ewer PhD, S H C Hodgson DPhil, S Jackson MRCP, D Jenkin MRCP, C C D Joe PhD, A M Lawrie PhD, A M Minassian DPhil, H Morrison MRCP, M E E Watson PhD, A D Douglas DPhil, A V S Hill FMedSci, T Lambe PhD, S C Gilbert PhD); Institute of Global Health, University of Siena, Siena, Brazil; (S A C Clemens PhD);Department of Paediatrics (S A C Clemens) and Clinical BioManufacturing Facility (C M Green PhD, R Tarrant PhD), University of Oxford, Oxford, UK; MRC Vaccines and Infectious Diseases Analytics Research Unit, Johannesburg, South Africa (S A Madhi PhD); Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, Brazil (L Y Weckx PhD); Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa (V Baillie PhD, C L Cutland PhD); Family Centre for Research with Ubuntu, Department of Paediatrics, University of Stellenbosch, Cape Town, South Africa (S L Barnabas PhD); Soweto Clinical Trials Centre, Soweto, South Africa (Q E Bhorat MSc); Perinatal HIV Research Unit (C Briner MBBCh, A Nana MPharm) and Wits Reproductive Health and HIV Institute (L Fairlie FCPaeds, C Hill BSc, G Kwatra PhD), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Clinical Sciences, Liverpool School of Tropical Medicine and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK (A M Collins PhD, D M Ferreira PhD, H Hill PhD); Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK (T C Darton DPhil); Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK (T C Darton); Division of Pulmonology, Groote Schuur Hospital and the University of Cape Town, South Africa (K Dheda FRCPCH); Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK (K Dheda); Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK (C J A Duncan DPhil); Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK (C J A Duncan); NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK (S N Faust PhD); Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK (S N Faust); School of Population Health Sciences, University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK (A Finn PhD); Department of Infection, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, UK (A L Goodman FRCP); MRC Clinical Trials Unit, University College London, London, UK (A L Goodman); NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (C A Green DPhil); St George’s Vaccine Institute, St George’s, University of London, London, UK (P T Heath FRCPCH); AstraZeneca BioPharmaceuticals, Cambridge, UK (I Hirsch PhD, R Mallory MD, J Vekemans MD, T L Villafana PhD); VIDA— Vaccines and Infectious Diseases Analytical Research Unit, Johannesburg, South Africa (A Izu PhD, A Koen MBChB); Severn Pathology, North Bristol NHS Trust, Bristol, UK (R Lazarus DPhil); NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, London, UK (V Libri MD FRCP); Department of Infection, Hull University Teaching Hospitals NHS Trust, UK (P J Lillie PhD); Escola Bahiana de Medicina e Saúde Pública, Salvador, Braziland Hospital São Rafael, Salvador, Brazil (A V A Mendes MD); Instituto D’Or, Salvador, Brazil (A V A Mendes); Department of Infectious Diseases, Universidade Federal do Rio Grande do Norte, Natal, Brazil (E P Milan MD); London Northwest University Healthcare, Harrow, UK (A C McGregor FRCPath); Setshaba Research Centre, Pretoria, South Africa (S D Payadachee MBChB); Department of Internal Medicine, Hospital Quinta D’Or, Rio de Janeiro, Brazil (A Pittella MD); Instituto D’Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil (A Pittella); Department of Internal Medicine, Universidade UNIGRANRIO, Rio de Janeiro, Brazil (A Pittella MD); NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK (K M Pollock PhD); Clinical Research Unit, Department of Clinical Medicine, Universidade Federal de Santa Maria, Santa Maria, Brazil (A V Schwarzbold PhD); College of Medical, Veterinary & Life Sciences, Glasgow Dental Hospital & School, University of Glasgow, Glasgow, UK (A Smith FRCPath); Division of Infectious Diseases, Boston Children’s Hospital, Boston, MA, USA (R Song); Infectious Diseases Service, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (E Sprinz MD); Clinical Infection Research Group, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK (R K Sutherland FRCP); MRC-University of Glasgow Centre for Virus Research & Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK (E C Thomson FRCP PhD); Department of Medicine, University of Cambridge, UK (M E Török FRCP); Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (M E Török); Heart Lung Research Institute, Department of Medicine, University of Cambridge and Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK (M Toshner MD); University of Nottingham and Nottingham University Hospitals NHS Trust, UK (D P J Turner PhD); Public Health Wales, Cardiff, Wales (C J Williams FFPH); Aneurin Bevan University Health Board, Newport, UK (C J Williams).UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D’Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland’s NIHR Clinical Research Network, and AstraZeneca.Múltipla - ver em Notas.A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 10¹⁰ viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 − relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs 71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.engElsevierBetacoronavirusCOVID-19EficáciaSARS-CoV-2SegurancaPandemiasAfrica do SulBrasilBetacoronavírusCOVID-19EfficiencySARS-CoV-2SecurityPandemicSouth AfricaBrazilSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83097https://www.arca.fiocruz.br/bitstream/icict/46170/1/license.txt36b51ef91c52b5338d9d29ba0cc807bcMD51ORIGINALVOYSEY et al Safety and efficacy... 2021 n.397 pg. 99–111.pdfVOYSEY et al Safety and efficacy... 2021 n.397 pg. 99–111.pdfapplication/pdf377590https://www.arca.fiocruz.br/bitstream/icict/46170/2/VOYSEY%20et%20al%20Safety%20and%20efficacy...%202021%20n.397%20pg.%2099%e2%80%93111.pdf0596e4d57fb7adbbaa734f24396658bbMD52TEXTVOYSEY et al Safety and efficacy... 2021 n.397 pg. 99–111.pdf.txtVOYSEY et al Safety and efficacy... 2021 n.397 pg. 99–111.pdf.txtExtracted texttext/plain80651https://www.arca.fiocruz.br/bitstream/icict/46170/3/VOYSEY%20et%20al%20Safety%20and%20efficacy...%202021%20n.397%20pg.%2099%e2%80%93111.pdf.txt0c9e7d5656b51d937f41718bcdb89130MD53icict/461702023-03-15 14:34:30.844oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:30Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| spellingShingle |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Voysey, Merryn Betacoronavirus COVID-19 Eficácia SARS-CoV-2 Seguranca Pandemias Africa do Sul Brasil Betacoronavírus COVID-19 Efficiency SARS-CoV-2 Security Pandemic South Africa Brazil |
| title_short |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_full |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_fullStr |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_full_unstemmed |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_sort |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| author |
Voysey, Merryn |
| author_facet |
Voysey, Merryn Clemens, Sue Ann Costa Madhi, Shabir A. Weckx, Lily Yin Folegatti, Pedro Moreira Aley, Parvinder K. Angus, Brian Baillie, Vicky L. Barnabas, Shaun L. Bhorat, Qasim E. Bibi, Sagida Briner, Carmen Cicconi, Paola Collins, Andrea M. Colin-Jones, Rachel Cutland, Clare L. Darton, Thomas C. Dheda, Keertan Duncan, Christopher J. A. Emary, Katherine R. W. Ewer, Katie J. Fairlie, Lee Feng, Shuo Ferreira, Daniela M. Finn, Adam Goodman, Anna L. Green, Catherine M. Green, Christopher A. Heath, Paul T. Hill, Catherine Hill, Helen Hirsch, Ian Hodgson, Susanne H. C. Izu, Alane Jackson, Susan Jenkin, Daniel Joe, Carina C. D. Kerridge, Simon Koen, Anthonet Kwatra, Gaurav Lazarus, Rajeka Lawrie, Alison M. Lelliott, Alice Libri, Vincenzo Lillie, Patrick J. Mallory, Raburn Mendes, Ana V. A. Milan, Eveline Pipolo Minassian, Angela M. McGregor, Alastair Morrison, Hazel Mujadidi, Yama F. Nana, Anusha O’Reilly, Peter J. Padayachee, Sherman D. Pittella, Ana Plested, Emma Pollock, Katrina M. Ramasamy, Maheshi N. Rhead, Sarah Schwarzbold, Alexandre V. Singh, Nisha Smith, Andrew Song, Rinn Snape, Matthew D. Sprinz, Eduardo Sutherland, Rebecca K. Tarrant, Richard Thomson, Emma C. Török, M. Estée Toshner, Mark Turner, David P. J. Vekemans, Johan Villafana, Tonya L. Watson, Marion E. E. Williams, Christopher J. Douglas, Alexander D. Hill, Adrian V. S. Lambe, Teresa Gilbert, Sarah C. Pollard, Andrew J. Faust, Saul N. |
| author_role |
author |
| author2 |
Clemens, Sue Ann Costa Madhi, Shabir A. Weckx, Lily Yin Folegatti, Pedro Moreira Aley, Parvinder K. Angus, Brian Baillie, Vicky L. Barnabas, Shaun L. Bhorat, Qasim E. Bibi, Sagida Briner, Carmen Cicconi, Paola Collins, Andrea M. Colin-Jones, Rachel Cutland, Clare L. Darton, Thomas C. Dheda, Keertan Duncan, Christopher J. A. Emary, Katherine R. W. Ewer, Katie J. Fairlie, Lee Feng, Shuo Ferreira, Daniela M. Finn, Adam Goodman, Anna L. Green, Catherine M. Green, Christopher A. Heath, Paul T. Hill, Catherine Hill, Helen Hirsch, Ian Hodgson, Susanne H. C. Izu, Alane Jackson, Susan Jenkin, Daniel Joe, Carina C. D. Kerridge, Simon Koen, Anthonet Kwatra, Gaurav Lazarus, Rajeka Lawrie, Alison M. Lelliott, Alice Libri, Vincenzo Lillie, Patrick J. Mallory, Raburn Mendes, Ana V. A. Milan, Eveline Pipolo Minassian, Angela M. McGregor, Alastair Morrison, Hazel Mujadidi, Yama F. Nana, Anusha O’Reilly, Peter J. Padayachee, Sherman D. Pittella, Ana Plested, Emma Pollock, Katrina M. Ramasamy, Maheshi N. Rhead, Sarah Schwarzbold, Alexandre V. Singh, Nisha Smith, Andrew Song, Rinn Snape, Matthew D. Sprinz, Eduardo Sutherland, Rebecca K. Tarrant, Richard Thomson, Emma C. Török, M. Estée Toshner, Mark Turner, David P. J. Vekemans, Johan Villafana, Tonya L. Watson, Marion E. E. Williams, Christopher J. Douglas, Alexander D. Hill, Adrian V. S. Lambe, Teresa Gilbert, Sarah C. Pollard, Andrew J. Faust, Saul N. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Voysey, Merryn Clemens, Sue Ann Costa Madhi, Shabir A. Weckx, Lily Yin Folegatti, Pedro Moreira Aley, Parvinder K. Angus, Brian Baillie, Vicky L. Barnabas, Shaun L. Bhorat, Qasim E. Bibi, Sagida Briner, Carmen Cicconi, Paola Collins, Andrea M. Colin-Jones, Rachel Cutland, Clare L. Darton, Thomas C. Dheda, Keertan Duncan, Christopher J. A. Emary, Katherine R. W. Ewer, Katie J. Fairlie, Lee Feng, Shuo Ferreira, Daniela M. Finn, Adam Goodman, Anna L. Green, Catherine M. Green, Christopher A. Heath, Paul T. Hill, Catherine Hill, Helen Hirsch, Ian Hodgson, Susanne H. C. Izu, Alane Jackson, Susan Jenkin, Daniel Joe, Carina C. D. Kerridge, Simon Koen, Anthonet Kwatra, Gaurav Lazarus, Rajeka Lawrie, Alison M. Lelliott, Alice Libri, Vincenzo Lillie, Patrick J. Mallory, Raburn Mendes, Ana V. A. Milan, Eveline Pipolo Minassian, Angela M. McGregor, Alastair Morrison, Hazel Mujadidi, Yama F. Nana, Anusha O’Reilly, Peter J. Padayachee, Sherman D. Pittella, Ana Plested, Emma Pollock, Katrina M. Ramasamy, Maheshi N. Rhead, Sarah Schwarzbold, Alexandre V. Singh, Nisha Smith, Andrew Song, Rinn Snape, Matthew D. Sprinz, Eduardo Sutherland, Rebecca K. Tarrant, Richard Thomson, Emma C. Török, M. Estée Toshner, Mark Turner, David P. J. Vekemans, Johan Villafana, Tonya L. Watson, Marion E. E. Williams, Christopher J. Douglas, Alexander D. Hill, Adrian V. S. Lambe, Teresa Gilbert, Sarah C. Pollard, Andrew J. Faust, Saul N. |
| dc.subject.other.pt_BR.fl_str_mv |
Betacoronavirus COVID-19 Eficácia SARS-CoV-2 Seguranca Pandemias Africa do Sul Brasil |
| topic |
Betacoronavirus COVID-19 Eficácia SARS-CoV-2 Seguranca Pandemias Africa do Sul Brasil Betacoronavírus COVID-19 Efficiency SARS-CoV-2 Security Pandemic South Africa Brazil |
| dc.subject.en.pt_BR.fl_str_mv |
Betacoronavírus COVID-19 Efficiency SARS-CoV-2 Security Pandemic South Africa Brazil |
| description |
SOUSA, Bruno Solano de Freitas Souza. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. |
| publishDate |
2021 |
| dc.date.accessioned.fl_str_mv |
2021-02-25T13:23:52Z |
| dc.date.available.fl_str_mv |
2021-02-25T13:23:52Z |
| dc.date.issued.fl_str_mv |
2021 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
VOYSEY, Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, v. 397, p. 99-111, 2021. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/46170 |
| dc.identifier.issn.pt_BR.fl_str_mv |
0140-6736 |
| dc.identifier.doi.none.fl_str_mv |
10.1016/S0140-6736(20)32661-1 |
| identifier_str_mv |
VOYSEY, Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, v. 397, p. 99-111, 2021. 0140-6736 10.1016/S0140-6736(20)32661-1 |
| url |
https://www.arca.fiocruz.br/handle/icict/46170 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/46170/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/46170/2/VOYSEY%20et%20al%20Safety%20and%20efficacy...%202021%20n.397%20pg.%2099%e2%80%93111.pdf https://www.arca.fiocruz.br/bitstream/icict/46170/3/VOYSEY%20et%20al%20Safety%20and%20efficacy...%202021%20n.397%20pg.%2099%e2%80%93111.pdf.txt |
| bitstream.checksum.fl_str_mv |
36b51ef91c52b5338d9d29ba0cc807bc 0596e4d57fb7adbbaa734f24396658bb 0c9e7d5656b51d937f41718bcdb89130 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1794075673556418560 |